VESIcare FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved November 19, 2004)
Brand name: VESIcare
Generic name: solifenacin succinate
Dosage form: Tablets
Company: Astellas Pharma US, Inc.
Treatment for: Overactive Bladder
VESIcare (solifenacin) is a muscarinic receptor antagonist for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
VESIcare LS is an oral suspension formulation of solifenacin for the treatment of
neurogenic detrusor overactivity in pediatric patients aged 2 years and older.
Development timeline for VESIcare
| Date | Article |
|---|---|
| May 27, 2020 | Approval FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Neurogenic Detrusor Overactivity (NDO) Pediatric Patients |
| Nov 19, 2004 | Approval FDA Approves Vesicare (solifenacin succinate) for the Treatment of Overactive Bladder |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
